Developer docs
API playgroundTry for free, no card

Search company profiles

AOA

Full company profile

uuid0000aml

Namestring
AOA
Legal namestring
AOA Dx Inc.
Websiteurl
aoadx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

AOA Dx is a US-based biotech company founded in 2020 and headquartered in Denver, Colorado, that develops liquid biopsy diagnostics for early cancer detection in women. Its lead product, AKRIVIS GD™, is a blood test intended for early detection of ovarian cancer in symptomatic women, addressing a clinical gap where the existing CA125 standard detects roughly 50% of early-stage cases and average diagnostic delay is approximately nine months. Underlying the test is the proprietary GlycoLocate™ platform, which combines lipidomics, metabolomics, and proteomics — including tumor-marker gangliosides (GD2, GD3) — with machine learning classifiers trained on a biobank of more than 2,200 patient samples.

The company is building its pipeline on an exclusive license to ganglioside-related IP from McGill University, a filed US patent (Application No. 63,087,427), and validated clinical performance of 92-94.8% early-stage sensitivity across independent US and UK cohorts. AOA Dx operates its own CLIA-capable laboratory in Denver, runs the multi-center OVERT prospective trial in the US and the APEX biobank-expansion study, and pursues a parallel laboratory-developed test (LDT) launch and FDA clearance pathway. Strategic partners include the University of Colorado Anschutz Medical Campus, the University of Manchester / Manchester University NHS Foundation Trust, Brigham and Women's Hospital (where Dr. Kevin Elias serves as OVERT Principal Investigator), BLOODPAC, and Sonrai Analytics for AI/data infrastructure.

AOA Dx has raised approximately $24 million across pre-seed, seed, and Series A rounds from investors including Joyance Partners, Avestria Ventures, Y Combinator, Good Growth Capital, Labcorp Venture Fund, and RH Capital. The company is pre-revenue with no commercial product on market; its go-to-market is built around diagnostic testing services delivered through its CLIA lab to healthcare providers (gynecologic oncologists, OB/GYNs, and primary care physicians) evaluating women with vague abdominal and pelvic symptoms suggestive of ovarian cancer. The company is seeking approximately $30 million in additional capital to bring AKRIVIS GD™ to market.

Short descriptiontext

AOA Dx is a US biotech developing AKRIVIS GD™, a multi-omic liquid biopsy blood test using machine learning on ganglioside and lipid biomarkers to detect early-stage ovarian cancer in symptomatic women, supported by its proprietary GlycoLocate™ platform and an in-house CLIA lab.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, ovarian cancer detection, multi-omics biomarker, women's health diagnostics, early cancer screening
Industry5 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

AOA Dx plans to commercialize its AKRIVIS GD™ diagnostic test as a laboratory-developed test (LDT) and through FDA-cleared device pathway. Revenue will be generated from clinical laboratory testing services provided to healthcare providers evaluating women with symptoms suggestive of ovarian cancer.

aoadx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1GlycoLocate™
Description

AI-enabled early detection cancer platform utilizing lipidomics to unlock next-generation biomarkers for early cancer diagnosis

aoadx.com
+1 more record
Core offering1 text field

AOA Dx develops and commercializes liquid biopsy blood tests for the early detection of cancers affecting women, anchored by AKRIVIS GD™, a first-in-class multi-omics blood test that detects early-stage ovarian cancer through proprietary tumor-marker ganglioside (GD2/GD3) biomarkers analyzed via LC-MS and machine learning. The test is delivered through the company's own CLIA-certified laboratory in Denver and is targeted at healthcare providers evaluating symptomatic women. The underlying discovery engine, GlycoLocate™, is an AI-enabled multi-omics platform combining lipidomics, metabolomics, proteomics, and clinical data to develop diagnostic assays across multiple cancer indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 92% early-stage (Stage I/II) sensitivity for ovarian cancer detection in symptomatic women, nearly double the ~50% sensitivity of CA125
+5 more records
Product overview1 text field

AOA Dx offers a unified product portfolio built on its proprietary GlycoLocate™ AI-enabled multi-omics platform. The platform serves as the core technology engine, integrating lipids, metabolites, proteins, and clinical data using machine learning for early cancer detection. The primary commercial product emerging from this platform is AKRIVIS GD™, a first-of-its-kind liquid biopsy test for early detection of ovarian cancer in symptomatic women. GlycoLocate™ functions as the underlying discovery and analytical engine, while AKRIVIS GD™ represents the first clinical application of this technology targeting ovarian cancer diagnostics.

Product and service1 record
1AKRIVIS GD™
CategoryCancer diagnostics / liquid biopsy
Description

AKRIVIS GD™ is a first-of-its-kind liquid biopsy blood test that uses a multi-omics approach combining tumor-associated gangliosides (GD2, GD3), lipids, metabolites, and proteins with AI and machine learning to detect early-stage ovarian cancer in symptomatic women. The test is delivered through AOA Dx's own CLIA-certified laboratory and targets healthcare providers (gynecologic oncologists, OB/GYNs, and primary care physicians) evaluating women with symptoms suggestive of ovarian cancer. Clinical performance: 92-94.8% sensitivity for early-stage detection, 94.4% sensitivity across all stages and subtypes, and 96.5% sensitivity / 80.6% specificity in symptomatic cohorts.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-05-20
Description

Strategic collaboration leveraging Sonrai's AI-powered cloud-based advanced analytics platform to integrate and analyze multi-modal data (multi-omic and clinical data) for biomarker validation and diagnostic accuracy enhancement. Sonrai provides bioinformatics expertise, pre-built machine learning tools, and secure cloud environment with role-based access for regulatory compliance.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Multi-year research collaboration providing clinically annotated patient samples and study design expertise. OCIG cohort used for multi-omic model training; demonstrated AUC of 93% for all-stage and 91% for early-stage ovarian cancer detection in approximately 500 samples.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-29
Description

Independent testing set partner providing prospectively collected symptomatic samples from intended-use population. Achieved AUC of 92% for all-stage and 88% for early-stage disease in real-world clinical cohort, validating robustness of AOA's approach.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

Public-private consortium aimed at accelerating development, validation, and accessibility of liquid biopsy assays. AOA Dx participating in Multi-Omics and Early Detection Working Groups, contributing lipidomic research and multi-omics expertise to establish standards for early detection assays.

5Professor Uri Saragovi (McGill University / Lady Davis Institute)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-08-30
Description

Exclusive license agreement to suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. Prof. Saragovi serves as scientific advisor and inventor; has published over 200 publications and 21 patents focusing on translational medicine and ganglioside targeting.

aoadx.com
6Dr. Anne-Marie Mes-Masson (Centre hospitalier de l'Université de Montréal)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Research collaboration on tumor-ganglioside screening studies for early cancer detection. Awarded RQRM grant supporting initial validation that gangliosides are accurate and reliable markers for early-stage cancer diagnosis.

aoadx.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1GRAIL
TypeDirect peer
Description

GRAIL developed Galleri, a multi-cancer early-detection blood test using methylation-based liquid biopsy and machine learning. Directly comparable to AOA Dx as a liquid biopsy company pursuing early cancer detection via novel biomarker classes plus advanced analytics, though GRAIL focuses on pan-cancer screening vs. AOA's symptomatic ovarian indication.

TypeDirect peer
Description

Guardant Health offers Guardant Shield for CRC screening and other liquid biopsy oncology tests using cfDNA. Comparable as a commercial-stage liquid biopsy company leveraging ML and proprietary chemistry to displace legacy screening/diagnostic modalities, with broader oncology portfolio than AOA Dx.

TypeBroad incumbent
Description

Exact Sciences commercializes Cologuard (CRC screening) and acquired Thrive Earlier Detection for its multi-cancer blood test. Comparable as a dominant liquid biopsy/screening diagnostics incumbent with deep commercial infrastructure. AOA Dx's CSO previously led R&D at Exact Sciences subsidiary Thrive, indicating direct talent and methodological overlap.

TypeDirect peer
Description

Freenome is developing a multi-omics blood test for early cancer detection combining cfDNA, proteins, and ML — closely paralleling AOA Dx's GlycoLocate multi-omics approach. Both target early detection in asymptomatic/symptomatic populations and have raised hundreds of millions in venture funding.

TypeDirect peer
Description

BillionToOne developed UNITY Fetal Risk Screen and Northstar liquid biopsy products using proprietary molecular counting and ML approaches. Comparable as a venture-backed diagnostics company using novel molecular biology plus data science to address oncology/prenatal indications, with overlapping target markets in women's health.

TypeDirect peer
Description

Natera commercializes Signatera (tumor-informed MRD testing) and Empower (prenatal screening). Comparable as a liquid biopsy company with established CLIA lab operations, FDA-cleared diagnostics, and active pursuit of oncology indications through proprietary chemistry and ML.

TypeEmerging player
Description

PGDx (acquired by Labcorp) developed NGS-based liquid biopsy assays for cancer. Direct comparable as an NGS/multi-omics liquid biopsy developer; notably, AOA Dx's Sr. Director of R&D and Director of R&D both previously led assay development at PGDx, indicating direct talent overlap and methodological kinship.

TypeEmerging player
Description

Bluestar Genomics developed epigenomic liquid biopsy tests for early cancer detection using 5-hydroxymethylcytosine biomarkers with ML. Comparable as an emerging multi-cancer/oncology liquid biopsy company pursuing novel biomarker classes plus ML analytics, though focused on different epigenetic markers than AOA's lipidomics approach.

TypeEmerging player
Description

Adela is developing a multi-cancer detection blood test using cell-free methylated DNA plus ML. Comparable as a venture-backed emerging liquid biopsy company pursuing early cancer detection through novel biomarker chemistry and machine learning, with similar pre-commercial/validation stage.

TypeEmerging player
Description

Angle plc developed Parsortix, a liquid biopsy system for capturing circulating tumor cells across multiple cancer indications. Comparable as an emerging liquid biopsy company targeting multiple oncology indications with proprietary sample-prep technology plus downstream analysis, addressing similar physician and laboratory customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AOA

Cancer Diagnosticsaoadx.com

AOA Dx is a US biotech developing AKRIVIS GD™, a multi-omic liquid biopsy blood test using machine learning on ganglioside and lipid biomarkers to detect early-stage ovarian cancer in symptomatic women, supported by its proprietary GlycoLocate™ platform and an in-house CLIA lab.

What AOA does

AOA Dx is a US-based biotech company founded in 2020 and headquartered in Denver, Colorado, that develops liquid biopsy diagnostics for early cancer detection in women. Its lead product, AKRIVIS GD™, is a blood test intended for early detection of ovarian cancer in symptomatic women, addressing a clinical gap where the existing CA125 standard detects roughly 50% of early-stage cases and average diagnostic delay is approximately nine months. Underlying the test is the proprietary GlycoLocate™ platform, which combines lipidomics, metabolomics, and proteomics — including tumor-marker gangliosides (GD2, GD3) — with machine learning classifiers trained on a biobank of more than 2,200 patient samples.

The company is building its pipeline on an exclusive license to ganglioside-related IP from McGill University, a filed US patent (Application No. 63,087,427), and validated clinical performance of 92-94.8% early-stage sensitivity across independent US and UK cohorts. AOA Dx operates its own CLIA-capable laboratory in Denver, runs the multi-center OVERT prospective trial in the US and the APEX biobank-expansion study, and pursues a parallel laboratory-developed test (LDT) launch and FDA clearance pathway. Strategic partners include the University of Colorado Anschutz Medical Campus, the University of Manchester / Manchester University NHS Foundation Trust, Brigham and Women's Hospital (where Dr. Kevin Elias serves as OVERT Principal Investigator), BLOODPAC, and Sonrai Analytics for AI/data infrastructure.

AOA Dx has raised approximately $24 million across pre-seed, seed, and Series A rounds from investors including Joyance Partners, Avestria Ventures, Y Combinator, Good Growth Capital, Labcorp Venture Fund, and RH Capital. The company is pre-revenue with no commercial product on market; its go-to-market is built around diagnostic testing services delivered through its CLIA lab to healthcare providers (gynecologic oncologists, OB/GYNs, and primary care physicians) evaluating women with vague abdominal and pelvic symptoms suggestive of ovarian cancer. The company is seeking approximately $30 million in additional capital to bring AKRIVIS GD™ to market.

AOA firmographics

Firmographics
Name
AOA
Legal name
AOA Dx Inc.
Website
https://aoadx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
AOA Dx is a US biotech developing AKRIVIS GD™, a multi-omic liquid biopsy blood test using machine learning on ganglioside and lipid biomarkers to detect early-stage ovarian cancer in symptomatic women, supported by its proprietary GlycoLocate™ platform and an in-house CLIA lab.
Ownership category
akta.pro rank

AOA industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • Liquid biopsy diagnostics
  • Ovarian cancer detection
  • Multi-omics biomarker
  • Women's health diagnostics
  • Early cancer screening

Where AOA is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices3 records

Markets served

AOA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: AOA Dx plans to commercialize its AKRIVIS GD™ diagnostic test as a laboratory-developed test (LDT) and through FDA-cleared device pathway. Revenue will be generated from clinical laboratory testing services provided to healthcare providers evaluating women with symptoms suggestive of ovarian cancer.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

AOA product offering

Product offering

Core offering

AOA Dx develops and commercializes liquid biopsy blood tests for the early detection of cancers affecting women, anchored by AKRIVIS GD™, a first-in-class multi-omics blood test that detects early-stage ovarian cancer through proprietary tumor-marker ganglioside (GD2/GD3) biomarkers analyzed via LC-MS and machine learning. The test is delivered through the company's own CLIA-certified laboratory in Denver and is targeted at healthcare providers evaluating symptomatic women. The underlying discovery engine, GlycoLocate™, is an AI-enabled multi-omics platform combining lipidomics, metabolomics, proteomics, and clinical data to develop diagnostic assays across multiple cancer indications.

Product overview

AOA Dx offers a unified product portfolio built on its proprietary GlycoLocate™ AI-enabled multi-omics platform. The platform serves as the core technology engine, integrating lipids, metabolites, proteins, and clinical data using machine learning for early cancer detection. The primary commercial product emerging from this platform is AKRIVIS GD™, a first-of-its-kind liquid biopsy test for early detection of ovarian cancer in symptomatic women. GlycoLocate™ functions as the underlying discovery and analytical engine, while AKRIVIS GD™ represents the first clinical application of this technology targeting ovarian cancer diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

  • GlycoLocate™: AI-enabled early detection cancer platform utilizing lipidomics to unlock next-generation biomarkers for early cancer diagnosis
  • AKRIVIS GD™

Products and services

  • AKRIVIS GD™ AKRIVIS GD™ is a first-of-its-kind liquid biopsy blood test that uses a multi-omics approach combining tumor-associated gangliosides (GD2, GD3), lipids, metabolites, and proteins with AI and machine learning to detect early-stage ovarian cancer in symptomatic women. The test is delivered through AOA Dx's own CLIA-certified laboratory and targets healthcare providers (gynecologic oncologists, OB/GYNs, and primary care physicians) evaluating women with symptoms suggestive of ovarian cancer. Clinical performance: 92-94.8% sensitivity for early-stage detection, 94.4% sensitivity across all stages and subtypes, and 96.5% sensitivity / 80.6% specificity in symptomatic cohorts.

Quantifiable outcome

  • 92% early-stage (Stage I/II) sensitivity for ovarian cancer detection in symptomatic women, nearly double the ~50% sensitivity of CA125
  • +5 more outcomes

Companies that use AOA

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

AOA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

AOA partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic, core and minor.

  • Sonrai AnalyticsstrategicTechnology or Integration · 20 May 2025Strategic collaboration leveraging Sonrai's AI-powered cloud-based advanced analytics platform to integrate and analyze multi-modal data (multi-omic and clinical data) for biomarker validation and diagnostic accuracy enhancement. Sonrai provides bioinformatics expertise, pre-built machine learning tools, and secure cloud environment with role-based access for regulatory compliance.
  • University of Colorado Anschutz Medical Campus - Ovarian Cancer Innovations Group (OCIG)coreStrategic or Co-development Partner · 29 April 2025Multi-year research collaboration providing clinically annotated patient samples and study design expertise. OCIG cohort used for multi-omic model training; demonstrated AUC of 93% for all-stage and 91% for early-stage ovarian cancer detection in approximately 500 samples.
  • The University of Manchester / Manchester University NHS Foundation TrustcoreStrategic or Co-development Partner · 29 April 2025Independent testing set partner providing prospectively collected symptomatic samples from intended-use population. Achieved AUC of 92% for all-stage and 88% for early-stage disease in real-world clinical cohort, validating robustness of AOA's approach.
  • BLOODPAC ConsortiumcoreStrategic or Co-development Partner · 20 February 2025Public-private consortium aimed at accelerating development, validation, and accessibility of liquid biopsy assays. AOA Dx participating in Multi-Omics and Early Detection Working Groups, contributing lipidomic research and multi-omics expertise to establish standards for early detection assays.
  • Professor Uri Saragovi (McGill University / Lady Davis Institute)coreTechnology or Integration · 30 August 2021Exclusive license agreement to suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies. Prof. Saragovi serves as scientific advisor and inventor; has published over 200 publications and 21 patents focusing on translational medicine and ganglioside targeting.
  • Dr. Anne-Marie Mes-Masson (Centre hospitalier de l'Université de Montréal)minorStrategic or Co-development Partner · 1 January 2020Research collaboration on tumor-ganglioside screening studies for early cancer detection. Awarded RQRM grant supporting initial validation that gangliosides are accurate and reliable markers for early-stage cancer diagnosis.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

AOA competitors and assessment

Company assessment

Direct peers

  • GRAIL: GRAIL developed Galleri, a multi-cancer early-detection blood test using methylation-based liquid biopsy and machine learning. Directly comparable to AOA Dx as a liquid biopsy company pursuing early cancer detection via novel biomarker classes plus advanced analytics, though GRAIL focuses on pan-cancer screening vs. AOA's symptomatic ovarian indication.
  • Guardant Health: Guardant Health offers Guardant Shield for CRC screening and other liquid biopsy oncology tests using cfDNA. Comparable as a commercial-stage liquid biopsy company leveraging ML and proprietary chemistry to displace legacy screening/diagnostic modalities, with broader oncology portfolio than AOA Dx.
  • Freenome: Freenome is developing a multi-omics blood test for early cancer detection combining cfDNA, proteins, and ML — closely paralleling AOA Dx's GlycoLocate multi-omics approach. Both target early detection in asymptomatic/symptomatic populations and have raised hundreds of millions in venture funding.
  • BillionToOne: BillionToOne developed UNITY Fetal Risk Screen and Northstar liquid biopsy products using proprietary molecular counting and ML approaches. Comparable as a venture-backed diagnostics company using novel molecular biology plus data science to address oncology/prenatal indications, with overlapping target markets in women's health.
  • Natera: Natera commercializes Signatera (tumor-informed MRD testing) and Empower (prenatal screening). Comparable as a liquid biopsy company with established CLIA lab operations, FDA-cleared diagnostics, and active pursuit of oncology indications through proprietary chemistry and ML.

Broad incumbents

  • Exact Sciences: Exact Sciences commercializes Cologuard (CRC screening) and acquired Thrive Earlier Detection for its multi-cancer blood test. Comparable as a dominant liquid biopsy/screening diagnostics incumbent with deep commercial infrastructure. AOA Dx's CSO previously led R&D at Exact Sciences subsidiary Thrive, indicating direct talent and methodological overlap.

Emerging players

  • Personal Genome Diagnostics (PGDx): PGDx (acquired by Labcorp) developed NGS-based liquid biopsy assays for cancer. Direct comparable as an NGS/multi-omics liquid biopsy developer; notably, AOA Dx's Sr. Director of R&D and Director of R&D both previously led assay development at PGDx, indicating direct talent overlap and methodological kinship.
  • Bluestar Genomics: Bluestar Genomics developed epigenomic liquid biopsy tests for early cancer detection using 5-hydroxymethylcytosine biomarkers with ML. Comparable as an emerging multi-cancer/oncology liquid biopsy company pursuing novel biomarker classes plus ML analytics, though focused on different epigenetic markers than AOA's lipidomics approach.
  • Adela: Adela is developing a multi-cancer detection blood test using cell-free methylated DNA plus ML. Comparable as a venture-backed emerging liquid biopsy company pursuing early cancer detection through novel biomarker chemistry and machine learning, with similar pre-commercial/validation stage.
  • Angle plc: Angle plc developed Parsortix, a liquid biopsy system for capturing circulating tumor cells across multiple cancer indications. Comparable as an emerging liquid biopsy company targeting multiple oncology indications with proprietary sample-prep technology plus downstream analysis, addressing similar physician and laboratory customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AOA social profiles

Digital presence

AOA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AOA leadership team

Management profile

Number of profiles

Profiles10 records

AOA funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AOA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AOA

What does AOA do?

AOA Dx develops and commercializes liquid biopsy blood tests for the early detection of cancers affecting women, anchored by AKRIVIS GD™, a first-in-class multi-omics blood test that detects early-stage ovarian cancer through proprietary tumor-marker ganglioside (GD2/GD3) biomarkers analyzed via LC-MS and machine learning. The test is delivered through the company's own CLIA-certified laboratory in Denver and is targeted at healthcare providers evaluating symptomatic women. The underlying discovery engine, GlycoLocate™, is an AI-enabled multi-omics platform combining lipidomics, metabolomics, proteomics, and clinical data to develop diagnostic assays across multiple cancer indications.

Is AOA a public or private company?

AOA is a private company. It is classified as venture growth investor backed and is currently operating.

When was AOA founded?

AOA was founded in 2020. It employs 51 to 100 people.

Where is AOA based?

AOA is headquartered in Denver, United States, in the North America region.

How does AOA make money?

One revenue line is on record: diagnostic Testing Services.

Who are AOA's main competitors?

Direct peers on record are GRAIL, Guardant Health, Freenome, BillionToOne and Natera. Exact Sciences is listed as a broad incumbent. Emerging players are Personal Genome Diagnostics (PGDx), Bluestar Genomics, Adela and Angle plc.

Does AOA have an API?

No public API is recorded for AOA.

What industry is AOA in?

AOA's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing. Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTEAMFund Releases Annual Impact Report - 144MM Unique Patients, 203MM Patient Services Cumulatively and AOA Dx Awarded Global Health Innovation Award - Ninth Consecutive Female Founder RecipientTEAMFund released its annual impact report at the AdvaMed MedTech Conference, citing 49 million patient services and 37 million unique patients served in the past year. The report also notes cumulative 203 million patient services and 144 million unique patients, with 67% served in India or Africa. TEAMFund awarded its Global Health Innovation Award to AOA Dx, its ninth consecutive female founder recipient.openPR.comMarket Trend Insights: The Impact of Recent Advancements on the Ovarian Cancer Diagnostics MarketThe ovarian cancer diagnostics market is projected to grow to $4.2 billion by 2030, expanding at a compound annual growth rate of 7.7%, driven by AI-driven diagnostic technologies, precision oncology funding, and biomarker-based testing. In May 2025, UK-based AI and data analytics firm Sonrai partnered with US biotechnology company AOA Dx to develop a serum-based multi-omic liquid biopsy test for early ovarian cancer detection, combining artificial intelligence with multi-omics approaches to improve diagnostic accuracy and patient outcomes.JD SupraMcGuireWoods Women’s Health Newsletter – March 2026: Regulatory and Transactional DevelopmentsThe McGuireWoods Women's Health Newsletter for March 2026 covers major transactional and regulatory developments in the women's health sector, including Hologic's acquisition by Blackstone and TPG for up to $18.3 billion and Pomelo Care's $92 million Series C round valuing the company at $1.7 billion. Research from AOA Dx shows women's health exits surpassed $100 billion over 25 years, with $34 billion in private investment since 2020. On the regulatory front, the FDA removed boxed warnings from six hormone replacement therapy products in February 2026, and Washington state proposed legislation restricting private equity ownership in healthcare practices.MedCity NewsMedCity FemFwd: Why Women’s Health Is a Scalable SectorThe article features a podcast discussion between MedCity News and Anna Jeter of AOA Dx about the company's recent report on women's health exits. The report challenges the perception that women's health is a niche market, presenting data showing over $100 billion in realized exits, 27 unicorns, and 272 exits between 2020-2024, with nearly half occurring in the last five years. The discussion emphasizes oncology as the largest hotspot and positions women's health as a proven, capital-efficient sector with significant strategic buyer interest.The Topeka Capital-JournalAOA Dx Releases First-Ever Comprehensive Women’s Health Exit Analysis, Revealing $100B+ in Realized Value Over 25 YearsAOA Dx released "Follow the Exits: Why Women\u2019s Health Is a Smart Bet in Healthcare," the first comprehensive analysis of exit outcomes in the women\u2019s health sector, at the 2026 J.P. Morgan Healthcare Conference in San Francisco. The report examined 272 publicly announced exits between 2000 and 2024, identifying over $91B in disclosed exit value across 159 transactions plus 4 additional billion-dollar exits in 2025, pushing total realized value beyond $100B, with 27 women\u2019s health companies achieving billion-dollar exits. The findings are intended to reposition women\u2019s health as a scaled, durable healthcare segment rather than a nascent market, influencing how investors, strategics, and policymakers evaluate the sector.RegisterguardAOA Dx Releases First-Ever Comprehensive Women’s Health Exit Analysis, Revealing $100B+ in Realized Value Over 25 YearsAOA Dx released a comprehensive analysis at the 2026 J.P. Morgan Healthcare Conference, showing over $100 billion in realized value from women’s health exits over 25 years. The report highlights significant growth and momentum in the sector, with nearly half of all exits occurring in the past five years.Columbia Daily TribuneAOA Dx Releases First-Ever Comprehensive Women’s Health Exit Analysis, Revealing $100B+ in Realized Value Over 25 YearsAOA Dx released Follow the Exits, the first comprehensive analysis of women’s health sector exit outcomes, at the 2026 J.P. Morgan Healthcare Conference, examining 272 publicly announced exits from 2000–2024. The report found $100B+ in total realized exit value, with nearly half of all exits occurring in the past five years, challenging the narrative that women’s health is a nascent market. Key findings include diagnostics delivering median exit values more than double industry benchmarks and 27 women’s health companies achieving $1B+ exits, signaling the sector’s maturity and growing strategic investor interest.The Clarion-LedgerAOA Dx Releases First-Ever Comprehensive Women’s Health Exit Analysis, Revealing $100B+ in Realized Value Over 25 YearsAOA Dx released a comprehensive analysis of women’s health exit outcomes at the 2026 J.P. Morgan Healthcare Conference, revealing over $100 billion in realized value from 272 exits between 2000 and 2024.